Protein that can stop the spread of breast cancer discovered

Breast cancer is one of the most rampant forms of cancer today, and is seen as the number one threat to the life of woman. While the cancer can occur in men too, it is commonly seen in women. Accordin

By: Pavitra Sampath | | Published: October 15, 2014 4:23 pm

Reduces breast cancer risk: Tea is rich in polyphenols that possess antioxidant and tumour fighting properties. A study claimed that the polyphenol content of tea decreases breast cancer risk by 21% in regular tea drinkers as compared to non-drinkers.

Breast cancer is one of the most rampant forms of cancer today, and is seen as the number one threat to the life of woman. While the cancer can occur in men too, it is commonly seen in women. According to recent statistics, breast cancer affects more women in urban areas than those living in rural regions. But there is some good news, scientists have discovered a new protein called Erbin, which is believed to be an anti-tumor factor in aggressive breast cancer. One of the first-known oncogenes has a protein partner that helps breast cancer proliferate and when it’s blocked, so is the cancer. The gene ErbB2, commonly called HER2, is highly expressed in about 25 percent of breast cancers. Scientists have now found the protein, which is highly expressed in these cancers and essential to ErbB2’s support of breast cancer.

When scientists interfered with the interaction between the two in mice, it inhibited tumor development and the usual spread to the lungs. The team documented the over expression of both in 171 cases of mostly aggressive human breast cancer as well.

The findings pointed towards a new therapeutic target for aggressive breast cancer and potentially an adjunct for women who become resistant to Herceptin, or trastuzumab, the drug commonly given to ErbB2-positive patients, said corresponding author Dr. Lin Mei. Additionally, Erbin could be a diagnostic biomarker that physicians look for in breast tissue biopsies.

Mei said that Erbin itself could be a novel target: disrupt the interaction and it would be therapeutic. Secondly, when a patient became Herceptin-resistant because the extracellular domain of ErbB2 was lost, this approach should still be effective because of the critical interaction of the two.

The Food and Drug Administration approved Herceptin for women with metastatic breast cancer who overexpress ErbB2, or HER2, in 1998 and, in 2006, as an adjuvant treatment in early stage HER2- positive breast cancer. The study is published in the journal PNAS.

Source: ANI

Image source: Getty

Published: October 15, 2014 4:23 pm

Disclaimer: TheHealthSite.com does not guarantee any specific results as a result of the procedures mentioned here and the results may vary from person to person. The topics in these pages including text, graphics, videos and other material contained on this website are for informational purposes only and not to be substituted for professional medical advice.

Latest Ebola News: Second healthcare worker tests positive for Ebola in Texas

Omega-3 supplements do nothing to normalise irregular heart beats

About The health Site

Useful Links